Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026 KRESLADI™ for severe LAD-I on track for March 28, 2026 PDUFA date Leadership updates with the appointments of Dr. Syed Rizvi , Chief Medical Officer, Christopher Stevens , Chief Operating Officer, and Sarbani Chaudhuri , Chief